Medmix (OTC:MDMXF) Stock, Quote.Headers.trade-ideas

Medmix AG delivers technologies in high-precision delivery devices and fluid mixing for applications. It is into two business areas Healthcare and Consumer & Industrial. The Healthcare business area is divided into the Dental, Drug Delivery, and Surgery segments. The Consumer & Industrial business area operates through the Industry and Beauty segments. The majority of revenue is from the Consumer & Industrial segment. In the Industry segment, dispensers, cartridges, and mixers are used in the construction, transportation (automotive, railways, and aerospace), electronics assembly, infrastructure, and DIY industries. Geographically, it operates in Europe the Middle East and Africa, the Americas, and Asia-Pacific.

Medmix AG

TAT Technologies Ltd. (TASE: TAT Tech,&nbsp;NASDAQ:&nbsp;TATT), a leading supplier of products and services for the commercial and military aviation industries and the ground defense industries, today announced that it has signed a five-year agreement with a major North American cargo carrier. &nbsp;
Under the terms of the agreement, TAT will provide repair and overhaul services under an MRO agreement for auxiliary power units (APUs) on the Carriers'&nbsp;Boeing 757 and 767 aircraft. The total contract value over the duration of the agreement is estimated at approximately $17 million.

News

TATT

Reported Earlier, TAT Technologies Secures $17M 5 Year MRO Deal With North American Cargo Carrier For Boeing 757 and 767 APU Services

NUBURU, Inc. ("NUBURU" or the "Company") (NYSE:<a href="https://www.benzinga.com/stock/BURU#NYSE">BURU</a>), a leading innovator in high-power and high-brightness industrial blue laser technology, today announced it received from NYSE Regulation a Warning Letter (the "Letter") as provided under Section 1009(a) of the NYSE American LLC Company Guide (the "Company Guide") describing violations by the Company of Sections 301 and 713 of the Company Guide. Section 301 of the Company Guide prohibits a listed company from issuing, or authorizing its transfer agent or registrar to issue or register, additional securities of a listed class until it has filed an application for the listing of such additional securities and received notification from the NYSE American that the securities have been approved for listing. Section 713 of the Company Guide requires stockholder approval when additional shares to be issued in connection with a transaction involve the sale, issuance, or potential issuance of common stock (or securities convertible into common stock) equal to 20% or more of outstanding stock for less than the greater of book or market value of the stock. As noted in the Letter, the Company issued approximately 4.6 million common shares between May 2024 and August 2024 in connection with the conversion of certain convertible promissory notes that NYSE has determined were in violation of these provisions.
The Company is implementing additional controls to avoid violations of such NYSE rules in the future.

Government

Regulations

BURU

Reported Earlier, NUBURU Addresses NYSE Compliance Violations Over 4.6M Share Issuance

NorthView Acquisition Corporation. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAC#NASDAQ">NVAC</a>) (the "Company") announced that it has received a notice (the "Notice") from The Nasdaq Stock Market LLC ("Nasdaq") stating that because the Company has not yet filed its Form 10-Q for the period ended September 30, 2024, the Company is no longer in compliance with Nasdaq Listing Rule 5250(c)(1), which requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission (the "SEC").
This notification has no immediate effect on the listing of the Company's shares on Nasdaq. However, if the Company fails to timely regain compliance with the Nasdaq Listing Rule, the Company's securities will be subject to delisting from Nasdaq.
Under Nasdaq rules, the Company has 60 calendar days to submit to Nasdaq a plan to regain compliance with the Nasdaq Listing Rule. If Nasdaq accepts the Company's plan, then Nasdaq may grant the Company up to 180 days from the prescribed due date for filing the Form 10-Q to regain compliance. If Nasdaq does not accept the Company's plan, then the Company will have the opportunity to appeal that decision to a Nasdaq Hearings Panel.
The Company is working diligently and expects to file its Form 10-Q within the 60-day period described above, which would eliminate the need for the Company to submit a formal plan to regain compliance.

NVAC

Reported Earlier, NorthView Acquisition Receives Nasdaq Notice For Dealy In Filing 10-Q

ServiceTitan, Inc. ("ServiceTitan"), the software platform that powers the trades, today announced the pricing of its initial public offering of 8,800,000 shares of its Class A common stock, at a public offering price of $71.00 per share. In addition, ServiceTitan has granted the underwriters a 30-day option to purchase up to an additional 1,320,000 shares of its Class A common stock at the initial public offering price, less underwriting discounts and commissions. The shares are expected to begin trading on the Nasdaq Global Select Market on December 12, 2024, under the ticker symbol "TTAN." The offering is expected to close on December 13, 2024, subject to customary closing conditions.

IPOs

TTAN

Reported Earlier, ServiceTitan Prices Initial Public Offering Of 8.8M Shares At $71/Share, Will Begin Trading On Nasdaq On December 12

Financial Institutions, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FISI#NASDAQ">FISI</a>) (the "Company"), parent company of Five Star Bank and Courier Capital, LLC, today announced the pricing of its previously announced underwritten public offering of 4,000,000 shares of its common stock at a public offering price of $25.00 per share. The expected proceeds to the Company, after deducting underwriting discounts and commissions but before deducting operating expenses payable by the Company, are approximately $95.0 million. In addition, the Company has granted the underwriters a 30-day option to purchase up to an additional 600,000 shares of Company common stock at the public offering price, less underwriting discounts, and commissions.
The Company intends to use the net proceeds from this offering for general corporate purposes which may include a balance sheet restructuring through the repositioning of a substantial portion of our available-for-sale debt securities portfolio to support continued growth as well as the repayment of indebtedness.

Offerings

FISI

Reported Earlier, Financial Institutions Prices $95M Common Stock Offering Of 4M Shares At $25/Share

AmpliTech Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMPG#NASDAQ">AMPG</a>, AMPGW))) (the "Company"), a designer, developer, and manufacturer of state-of-the-art signal processing components for satellite, Public and Private 5G, and other communications networks, including the design of complete 5G/6G systems and a global distributor of packages and lids for integrated circuits assembly, today announced that it has entered into one or more securities purchase agreements with certain institutional investors to purchase 1,352,500 shares of common stock (the "Securities") at an offering price of $1.60 per share, in a registered direct offering.
The gross proceeds to the Company from the registered direct offering are estimated to be approximately $2.2 million before deducting the placement agent's fees and other estimated offering expenses. The offering is expected to close on or about December 13, 2024, subject to the satisfaction of customary closing conditions.

AMPG

Reported Earlier, AmpliTech Prices $2.2M Registered Direct Offering Of 1.35M Shares At $1.60/Share

NewAmsterdam Pharma Company N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAMS#NASDAQ">NAMS</a>, "NewAmsterdam" or the "Company"))), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease ("CVD") with elevated low-density lipoprotein cholesterol ("LDL-C"), for whom existing therapies are not sufficiently effective or well-tolerated, today announced the pricing of the previously announced underwritten public offering of (i) 12,117,347 of the Company's ordinary shares, nominal value €0.12 per share (the "Ordinary Shares"), at a public offering price of $24.50 per share and (ii) to certain investors that so choose in lieu of Ordinary Shares, pre-funded warrants to purchase 4,882,653 Ordinary Shares at a public offering price of $24.4999 per pre-funded warrant, which represents the per share public offering price for the Ordinary Shares less the $0.0001 per share exercise price for each such pre-funded warrant ("Pre-Funded Warrants," such offering, the "Offering"). The proceeds to the Company from the Offering, before deducting underwriting discounts and commissions and offering expenses payable by the Company, are expected to be approximately $416.5 million. In addition, the Company has granted the underwriters a 30-day option to purchase up to an additional 2,550,000 Ordinary Shares at the public offering price, less underwriting discounts and commissions. The Offering is expected to close on or about December 13, 2024, subject to satisfaction of customary closing conditions.

NAMS

Reported Earlier, NewAmsterdam Pharma Prices $416.5M Upsized Public Offering At $24.50/Share  to Advance Cardiovascular Treatments

Chewy, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHWY#NYSE">CHWY</a>) ("Chewy"), a trusted destination for pet parents and partners everywhere, announced today the pricing of an underwritten public offering of 15,852,886 shares of its Class A common stock, par value $0.01 per share, by Buddy Chester Sub LLC (the "Selling Stockholder"), which is an entity affiliated with funds advised by BC Partners Advisors LP ("BC Partners"), Chewy's largest shareholder (the "Offering"). The Selling Stockholder granted the underwriter a 30-day option to purchase up to an additional 2,377,932 shares of Class A common stock. Chewy will not sell any shares of its Class A common stock in the Offering and will not receive any proceeds from the sale of the shares of Class A common stock being offered by the Selling Stockholder.
In addition, as previously announced, concurrent with the closing of the Offering, Chewy has agreed to purchase from the Selling Stockholder $50 million of Chewy's Class A common stock at a price per share equal to the per share purchase price to be paid by the underwriter in the Offering (the "Concurrent Repurchase"). The Concurrent Repurchase was approved by a special committee of Chewy's Board of Directors, consisting solely of independent and disinterested directors not affiliated with BC Partners. The repurchased shares will be cancelled and retired upon completion of the Concurrent Repurchase. The Concurrent Repurchase is being executed separately from the Company's existing $500 million share repurchase program authorized on May 24, 2024, which will be unaffected by this transaction. The Concurrent Repurchase is expected to be consummated concurrently with the Offering. The Offering is not conditioned upon the closing of the Concurrent Repurchase, but the Concurrent Repurchase is conditioned upon the closing of the Offering.

Buybacks

CHWY

Reported Earlier, Chewy's Largest Shareholder Sells Over 15M Shares in Public Offering, Announces $50M Share Repurchase Concurrent With Major Stock Offering

HUTCHMED (China) Limited ("<a href="https://www.globenewswire.com/Tracker?data=oTcdhXadX19k0ZtVaSkHlIFOWdz_eupbrU5kN4qdyDAEBCFkFGgJtifODWXWuyyWT_Ylh_oU5Si7y6NT9Y1O8g==">HUTCHMED</a>") (Nasdaq/AIM:HCM; HKEX:13) today announces that the Center for Drug Evaluation of China's National Medical Products Administration ("NMPA") has granted Breakthrough Therapy Designation ("BTD") to the combination of ORPATHYS&#xAE; (savolitinib) and TAGRISSO&#xAE; (osimertinib) for the treatment of patients with locally advanced or metastatic epidermal growth factor receptor ("EGFR") mutation‑positive non‑small cell lung cancer ("NSCLC") with MET amplification after disease progression on EGFR inhibitor therapy. ORPATHYS&#xAE; is an oral, potent and highly selective MET tyrosine kinase inhibitor ("TKI"). TAGRISSO&#xAE; is a third-generation, irreversible EGFR TKI.
This treatment combination is being evaluated in China in the ongoing multi-center, open-label, randomized, controlled, Phase III SACHI trial. The study is investigating the efficacy and safety of a combination of ORPATHYS&#xAE; and TAGRISSO&#xAE; compared to platinum-based doublet-chemotherapy (pemetrexed plus cisplatin or carboplatin), the standard‑of‑care treatment option, in patients with locally advanced or metastatic NSCLC with MET amplification after failure of EGFR inhibitor therapy. The primary endpoint of the study is progression-free survival ("PFS") as assessed by investigators. Other endpoints include PFS assessed by an independent review committee, overall survival (OS), objective response rate (ORR), duration of response (DoR), disease control rate (DCR), time to response (TTR), and safety (<a href="https://www.globenewswire.com/Tracker?data=5t4GKVCkKXA8Ab1R2suFdTbevKXKwNJDJuBwPfy8puyY6egl79Z9eui9QHejf_OxruQYkBTlvIEeMjVFcI_Lt1SM-RdlWomkUjUU1sJNRyyPjGTzq7fr-R7Iq2svAB_v">NCT05015608</a>).
NMPA grants BTD to new drugs that treat life-threatening diseases or serious conditions for which there are no effective treatment options, and where clinical evidence demonstrates significant advantages over existing therapies. Drug candidates with BTD may be considered for conditional approval and priority review when submitting an NDA. This indicates that the development and review of the therapy for this disease indication may be expedited, to address patients' unmet needs more quickly.

Reported Earlier, HUTCHMED's ORPATHYS and TAGRISSO Combo Gains Therapy Designation in China for Advanced Lung Cancer

Ormat Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORA#NYSE">ORA</a>) ("Ormat" or the "Company"), a leading geothermal and renewable energy technology company, announced today the pricing of an underwritten secondary offering of 3,700,000 shares of its common stock on behalf of ORIX Corporation. The offering is expected to close on December 13, 2024, subject to customary closing conditions. Ormat is not offering any of its common stock in the offering for its own account and will not receive any proceeds from the sale of the shares being offered by the selling stockholder.
Goldman Sachs &amp; Co. LLC is acting as the sole book-running manager and underwriter for the offering. The shares of common stock are being sold to the public at an initial price of $76.20 per share. Goldman Sachs &amp; Co. LLC will have a 30-day option to purchase up to an additional 555,000 shares of Ormat's common stock from ORIX Corporation.

Reported Earlier, Ormat Selling Stockholder Priced Public Offering of 3.7M Common Stock At $76.20/Share

Nutanix, Inc. ("Nutanix") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTNX#NASDAQ">NTNX</a>) , a leader in hybrid multicloud computing, today announced the pricing of $750 million aggregate principal amount of 0.50% convertible senior notes due 2029 (the "notes") in a private placement (the "offering") to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). Nutanix has granted the initial purchasers of the notes an option to purchase up to an additional $112.5 million aggregate principal amount of the notes within a 13-day period from, and including, the initial issuance date of the notes. The sale of the notes to the initial purchasers is expected to settle on December 16, 2024, subject to satisfaction of customary closing conditions.
Nutanix estimates that the net proceeds from the offering will be approximately $734.3 million (or approximately $844.5 million if the initial purchasers exercise their option to purchase additional notes in full), after deducting the initial purchasers' discount and estimated offering expenses payable by Nutanix. Nutanix intends to use (i) approximately $95.5 million of the net proceeds from the offering to repurchase $75.0 million aggregate principal amount of its outstanding 0.25% Convertible Senior Notes due 2027 (the "2027 notes") and (ii) approximately $200.0 million of the net proceeds from the offering to repurchase approximately 3.1 million shares of its Class A common stock, in each case, in privately negotiated transactions effected through one of the initial purchasers of the notes or its affiliates, acting, as Nutanix's agent, at a purchase price per share equal to the closing price of Nutanix's Class A common stock on December 11, 2024, which was $64.78 per share (the "Share Repurchases"). The Share Repurchases will not reduce the amount available for future repurchases under Nutanix's existing share repurchase program. We intend to use the remaining net proceeds of the offering for general corporate purposes, including working capital, capital expenditures and potential acquisitions. From time to time, Nutanix evaluates potential acquisitions of businesses, technologies or products. Currently, however, Nutanix does not have any understandings or agreements with respect to any acquisitions.

NTNX

Reported Earlier, Nutanix Prices $750M 0.50% Convertible Senior Notes Offering

BriaCell Therapeutics Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCTX#NASDAQ">BCTX</a>, BCTXW))) (TSX:<a class="ticker" href="https://www.benzinga.com/stock/BCT#TSX">BCT</a>) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announced the pricing of an underwritten public offering of 7,400,000 common shares and warrants to purchase 7,400,000 common shares at a combined public offering price of $0.75 per share and associated warrant. The warrants will have an exercise price of $0.9375 per share and will be immediately exercisable upon issuance for a period of five years following the date of issuance. All of the common shares and associated warrants in the offering are being offered by the Company. Total gross proceeds from the offering, before deducting underwriters discounts and other offering expenses, are expected to be approximately $5.55 million. The offering is expected to close on December 13, 2024, subject to satisfaction of customary closing conditions. The Company is relying upon the exemption set forth in Section 602.1 of the TSX Company Manual, which provides that the TSX will not apply its standards to certain transactions involving eligible interlisted issuers on a recognized exchange, such as Nasdaq.
The Company intends to use the net proceeds from the offering for working capital requirements, general corporate purposes, and the advancement of business objectives.

BCTX

TSX:BCT

Reported Earlier, BriaCell Therapeutics Prices $5.5M Public Offering Of 7.4M Shares At $0.75/Share For Working Capital Requirements

On Wednesday, Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) rolled out iOS 18.2, and it's packed with AI-powered features that might just make your iPhone feel like it's from the future.
From crafting custom emojis to pointing your camera at objects for instant information, iOS 18.2 has something for everyone — well, almost everyone. Here's the lowdown.
What's New In iOS 18.2
Apple Intelligence is finally stepping into the spotlight. With ChatGPT-powered Siri, you can have deeper, more intuitive conversations with your virtual assistant. But that's not all:
Genmoji: Design custom emojis that look and act like you. Yes, your emoji can now have your quirks!
Image Playground: Transform text prompts into stunning visuals with this app.
Visual Intelligence (iPhone 16 Exclusive): Point your camera at anything—be it a dish, a book, or a mysterious bug—and let Apple's visual search tool do its magic.
See Also: <a href="https://www.benzinga.com/24/12/42384578/iphone-charging-cables-arent-all-safe-how-hackers-turn-them-into-tools-of-espionage">Not All iPhone Charging Cables Are Safe: Here&#8217;s How Hackers Turned Them Into Tools Of Espionage</a>
Which Devices Are Invited To The AI Party
Apple Intelligence isn't for everyone. Only users with iPhone 15 Pro, Pro Max, and all iPhone 16 models, and iPads and Macs with an M1 chip or newer, can access these new features.
Before The Download, Prepare Your Device
Step I: Backup your iPhone – Better safe than sorry.
Step II: Update to iOS 18.1.1 – A smoother transition awaits.
Step III: Free up storage – No room? No update.
Bonus Step: Join the Apple Intelligence waitlist – It's your golden ticket to AI features.
Subscribe to the&nbsp;<a href="https://bztechtrends.beehiiv.com/subscribe" target="_blank" rel="noreferrer noopener">Benzinga Tech Trends newsletter</a>&nbsp;to get all the latest tech developments delivered to your inbox.
How To Get iOS 18.2
Apple has already started rolling out the update. You can simply download it following a few steps: Go to Settings &gt; General &gt; Software Update. Now, hit Update Now and follow the prompts.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="545" height="1024" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/12015544/IMG_0018-545x1024.jpeg" alt="" class="wp-image-688896" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/12015544/IMG_0018-545x1024.jpeg 545w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/12015544/IMG_0018-160x300.jpeg 160w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/12015544/IMG_0018.jpeg 575w" sizes="(max-width: 545px) 100vw, 545px" /></figure>
Check out more of Benzinga's Consumer Tech coverage by <a href="https://www.benzinga.com/topic/consumer-tech" target="_blank" rel="noreferrer noopener">following this link</a>.
Photo Courtesy: El editorial On Shutterstock.com
Read Next:
<ul>
<li><a href="https://www.benzinga.com/tech/24/11/41931521/apples-2024-mac-mini-is-a-compact-powerhouse-but-its-power-button-placement-is-not-the-most-accessible-here-are-some-workable-fixes">Apple&#8217;s 2024 Mac Mini Is A Compact Powerhouse, But Its Power Button Placement Is Not The Most Accessible: Here Are Some Workable Fixes</a></li>
</ul>
Disclaimer: This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.

Tech

AAPL

How To Unlock Apple Intelligence Features With iOS 18.2: Everything You Need To Know

Faraday Future Intelligent Electric Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFIE#NASDAQ">FFIE</a>) ("Faraday Future", "FF" or "Company"), a California-based global shared intelligent electric mobility ecosystem company, today announced that Suede Brooks, a prominent YouTube influencer, fashion model, and designer, will take delivery of her new FF 91 2.0 Futurist Alliance EV at a ceremony with FF executives on Thursday, December 12, in suburban Los Angeles.

FFIE

GOOG

GOOGL

Faraday Future Hands Over FF 91 Futurist Alliance EV to YouTube Star Suede Brooks

SpaceX&#8216;s valuation reportedly hit $350 billion after the company and its investors agreed to purchase $1.25 billion of insider shares. Now, founder Elon Musk has revealed that almost none of the existing investors wanted to sell their holdings.
What Happened: The company and its investors agreed to buy insider shares at $185 a share, Bloomberg <a href="https://www.bloomberg.com/news/articles/2024-12-10/spacex-share-sale-is-said-to-value-company-at-about-350-billion">reported</a>, citing an internal email. SpaceX alone is offering to buy as much as $500 million in common stock as part of the offer, the report added.
The new valuation represents a 67% surge from the company&#8217;s <a href="https://www.benzinga.com/news/24/06/39519229/elon-musk-dismisses-rumors-of-spacex-ipo-as-it-reportedly-seeks-210b-valuation-pressure-for-short-te">previous valuation of $210 billion</a> it hit in a secondary share sale in June. 
The new valuation makes SpaceX the most valuable private startup in the world. Its valuation, in fact, trumps the valuation of listed rival Boeing Co. Boeing has a market cap of only $122.78 billion as of last close.
Why It Matters: SpaceX is privately held, unlike Musk's Tesla which is a publicly listed company. The secondary offering gives employees and shareholders the choice of selling shares they hold in the company and generating liquidity.
&#8220;What's really crazy about this is that almost no investors wanted to sell shares even at a $350B valuation! SpaceX reduced the amount of shares it bought back from employees in order to allow some new investors in,&#8221; SpaceX CEO Elon Musk said on Wednesday about the insider share sale, confirming the new valuation.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">What's really crazy about this is that almost no investors wanted to sell shares even at a $350B valuation! SpaceX reduced the amount of shares it bought back from employees in order to allow some new investors in.
&mdash; Elon Musk (@elonmusk) <a href="https://twitter.com/elonmusk/status/1866789126814699824?ref_src=twsrc%5Etfw">December 11, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Musk has <a href="https://www.benzinga.com/news/24/06/39519229/elon-musk-dismisses-rumors-of-spacex-ipo-as-it-reportedly-seeks-210b-valuation-pressure-for-short-te" target="_blank" rel="noreferrer noopener">previously dismissed</a> the possibility of a SpaceX initial public offering (IPO), citing the intense pressure for short-term results faced by publicly listed companies.
Despite SpaceX being private, investors can leverage Destiny Tech100 Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DXYZ#NYSE">DXYZ</a>) and Cathie Wood‘s Ark Venture Fund (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARKVX#NASDAQ">ARKVX</a>) to participate in the Musk-led space company's growth.
Check out more of Benzinga&#8217;s Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/tech/24/12/42432727/lucids-gravity-gets-official-range-estimate-higher-than-teslas-model-x-but-lower-than-its-own-air-sedan" target="_blank" rel="noreferrer noopener">Lucid's Gravity Gets Official Range Estimate: Higher Than Tesla's Model X, But Lower Than Its Own Air Sedan</a></li>
</ul>
Photo courtesy: Shutterstock

SPACE

ARKVX

DXYZ

SpaceX Hits $350 Billion Valuation In Insider Share Sale: CEO Elon Musk Says 'No Investors Wanted To Sell Shares'

Following a strategic review of the Company's software investment strategy, <a href="https://www.globenewswire.com/Tracker?data=U9tRSza6x2H2zLkUeUxIcYMddxayjAkmoq404GWwzjHPidt0dbTh3kiq2MH_fIaaj4YiUTwnsNhuSLcuTqJJc7_AYcZyWC_0FuVIdxer8wwPmJW1W4MbcVwgCWUKuW3d6p7z3KVUpvCVJarm5NbOUB-N91BjxbYs4u4nFldMLWSqTcS25cE8oQdDbuH01dTG2zCw9gHDjvQWcgjQqVB1jPkTnButOBVPjT_hnl_liRzClS8ek_-WhfjqxtCfHQmdNgiQEzS2JDL0GKdItFfY6Q==">3D Systems</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DDD#NYSE">DDD</a>) today announced that it has signed a definitive agreement to sell&nbsp;its&nbsp;Geomagic software portfolio to the Manufacturing Intelligence Division of Hexagon, a global leader in digital reality solutions, combining sensor, software, and autonomous technologies, for $123 million. The transaction is expected to close in the first half of 2025, following the completion of customary regulatory reviews. The Geomagic product portfolio is a powerful, proven integrated software tool kit that includes Design X, Control X, Freeform, Wrap, and Geomagic for SolidWorks. The Geomagic portfolio has built a strong user base in, among other things, the market for creating digital models from physical objects that can then be used to manufacture the finished component. This process, commonly known as ‘reverse engineering,' automates the processing of scan data captured with a 3D scanner to create accurate CAD models. Certain Geomagic products can also be used to design from scratch or modify existing models and to accurately measure and inspect parts for quality control purposes when finished. As a leader in scanning technologies, Hexagon is ideally positioned to harness the power of the Geomagic portfolio to offer a more complete scan-to-CAD workflow, to bridge the physical and digital worlds.
Following the divestiture, 3D Systems will focus on its software platforms that are core to customer adoption and application of its 3D printing technologies. These specifically include 3D Sprint, 3DXpert, and Oqton Industrial Manufacturing OS, each of which bring unique value to customers targeting large-scale, production applications. By concentrating development resources on these platforms, 3D Systems believes it can accelerate its strategic software development efforts and augment its product offerings to empower customers to unlock the full potential of AM. This focus is particularly important in order to increasingly leverage the capabilities of AI and machine learning, as these powerful new tools become more accessible to companies targeting, high-reliability production environments and other critical industrial settings. By focusing on these high-ROI, mission-critical software offerings, the Company will better enable the widespread&nbsp;adoption of additive manufacturing significantly enhancing customer and shareholder value.
&nbsp;

Asset Sales

3D Systems Sells Geomagic Software Portfolio for $123 Million, Shifts Focus to Core 3D Printing Tools

Nordson Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDSN#NASDAQ">NDSN</a>) fell by 5.43% to $236.01 in after-hours on Wednesday as the company revenue guidance for the fiscal year 2025 was below analyst expectations. However, the technical analysis using simple moving averages indicates that the stock remains under pressure pointing toward a bearish trend.
What Happened: Nordson <a href="https://www.benzinga.com/insights/earnings/24/12/42449106/earnings-summary-nordson-q4">recorded a net income</a> of $122 million for the fourth quarter of the current fiscal, which was less than the net income of $128 million in the same quarter of the previous fiscal year.
The company which makes spraying equipment for agricultural use had its net sales increase by 4% year-on-year. It recorded $744 million in revenue for the period, compared to $719 million in the prior year&#8217;s fourth quarter.
On a full-year basis, Nordson recorded record sales of $2.7 billion, reflecting 2% growth over last fiscal&#8217;s record sales. The net income for the year was $467 million, a decrease from the prior year's net income of $487 million.
Nordson revenue guidance for the upcoming fiscal 2025 was between $2.75 billion and $2.87 billion, which was below analysts&#8217; expectations of $2.93 billion, according to data compiled by LSEG.
Also read: <a href="https://www.benzinga.com/insights/earnings/24/12/42449106/earnings-summary-nordson-q4">Earnings Summary: Nordson Q4</a>
Why It Matters: Nordson Corp&#8217;s stock has declined by 3.52% on a year-to-date basis and advanced by 7.23% in the last six months. This compares to a 31.55% and 11.81% performance by the Nasdaq 100 Index in the same period, respectively.
From a technical perspective, the analysis of daily moving averages indicates that the stock may be under pressure.
The stock ended at $236.01 in after-hours on Wednesday. This was below its eight and 20-day simple moving averages, of $255.12 and $256.39, respectively. As per <a href="https://pro.benzinga.com/dashboard">Benzinga Pro data</a>, its current stock price was also lower than the 50 and 200-day moving average prices at $255.04 and $251.99, respectively.
This trend indicates that the stock is experiencing a bearish divergence. The stock price could be attempting to recover but the momentum is not strong enough to push it above the moving averages. On the other hand, the relative strength index of 39.44 suggests the stock is near the oversold territory.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="576" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/12011114/nordson-Chart-1024x576.png" alt="" class="wp-image-688857" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/12011114/nordson-Chart-1024x576.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/12011114/nordson-Chart-300x169.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/12011114/nordson-Chart-768x432.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/12011114/nordson-Chart-1536x864.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/12011114/nordson-Chart.png 1920w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Benzinga&#8217;s <a href="https://www.benzinga.com/quote/NDSN">technical analysis scorecard</a>, scores the company at 66 points on 100.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/quote/NDSN"><img loading="lazy" decoding="async" width="496" height="142" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/12011037/Tech-A-Nordon.png" alt="" class="wp-image-688856" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/12011037/Tech-A-Nordon.png 496w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/12011037/Tech-A-Nordon-300x86.png 300w" sizes="(max-width: 496px) 100vw, 496px" /></a></figure>
What Are Analysts Saying: According to <a href="https://www.benzinga.com/">Benzinga</a>, Nordson has a consensus price target of $275.29 based on the ratings of eight analysts. The highest price target out of all the <a href="https://www.benzinga.com/quote/NDSN/analyst-ratings">analysts tracked by Benzinga</a> is $315 issued by DA Davidson as of Feb. 27, 2024. The lowest target price is $225 issued by Loop Capital on March 21, 2023.
The average price target of $284.67 between two changes from Baird, and DA Davidson implies a 20.62% upside for Nordson.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/quote/NDSN/analyst-ratings"><img loading="lazy" decoding="async" width="945" height="352" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/12010944/Nordson-ANR.png" alt="" class="wp-image-688853" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/12010944/Nordson-ANR.png 945w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/12010944/Nordson-ANR-300x112.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/12010944/Nordson-ANR-768x286.png 768w" sizes="(max-width: 945px) 100vw, 945px" /></a></figure>
Image via Nordson
Read Next: 
<a href="https://www.benzinga.com/markets/equities/24/12/42435201/elon-musks-net-worth-surpasses-market-cap-of-us-giants-like-bofa-johnson-johnson-salesforce-chevron-coca-cola-and-more-only-25-companies-have-higher-market-cap">Elon Musk&#8217;s Net Worth Surpasses Market Cap Of US Giants Like BofA, Johnson &amp; Johnson, Salesforce, Chevron, Coca-Cola And More: Only 25 Companies Have Higher Market Cap</a>

Equities

Markets

NDSN

Nordson Corporation Stock Slides After Hours As Company Projects Lower FY25 Revenue; Technical Analysis Predicts Bearish Trends

AI chipmaker Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) has reportedly added hundreds of staff in China this year.
What Happened: Nvidia will now end the year with nearly 4,000 employees, marking a significant increase from the 3,000 at the onset of the year, <a href="https://www.bloomberg.com/news/articles/2024-12-12/nvidia-steps-up-hiring-in-china-to-focus-on-ai-driven-cars">reported</a> Bloomberg, citing people familiar with the matter.
The increase in workforce in China is aimed at improving the company&#8217;s research capabilities and focus on new autonomous driving technologies, the report said.
The report said Nvidia has added 200 people to its team of researchers in Beijing working on autonomous driving. People have also been added to the company&#8217;s after-sales service and networking software development teams.
Nvidia has been developing driving automation and AI software for over a decade, the report noted, while adding that the efforts are yet to yield results.
Why It Matters: Overall, Nvidia had 29,600 employees in 36 countries around the world as of February. The company has been adding more to meet the <a href="https://www.benzinga.com/news/earnings/24/11/42099904/nvidia-beats-q3-revenue-eps-estimates-supply-constraints-ding-stock-huang-says-age-of-ai-is-in-full-steam">rising demand for its AI chips</a>. 
China has seen a surge in EV sales and companies over the past few years. Autonomous driving technology, therefore, has significant demand in the country.
However, earlier this week, China launched an <a href="https://www.benzinga.com/news/legal/24/12/42404352/nvidia-china-antitrust-probe-may-remain-unsolved-in-near-term-says-top-analyst-investors-should-be-prepared-for-increased-scrutiny">antitrust investigation</a> centered on Nvidia&#8217;s acquisition of Israeli networking company&nbsp;Mellanox Technologies, approved in 2020, and its potential violations of China&#8217;s anti-monopoly laws.
Check out more of Benzinga's Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/tech/24/12/42429588/gms-cruise-exit-draws-sharp-reaction-from-co-founder-kyle-vogt-tesla-ceo-elon-musk-says-autonomous-driving-is-a-very-hard-problem" target="_blank" rel="noreferrer noopener">GM's Cruise Exit Draws Sharp Reaction From Co-Founder Kyle Vogt: Tesla CEO Elon Musk Says Autonomous Driving Is A ‘Very Hard Problem'</a></li>
</ul>
Photo courtesy: Shutterstock

Global

NVDA

Nvidia Adds Hundreds To Its Workforce In China To Build Autonomous Driving Tech Amid Antitrust Investigation: Report

Japan-based cryptocurrency exchange Coincheck started trading on the Nasdaq stock exchange Wednesday following a strategic merger with a special purpose acquisition company.
What happened: Coincheck Group N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNCK#NASDAQ">CNCK</a>), the holding company of the Tokyo-headquartered firm, merged with Thunder Bridge Capital Partners IV, allowing its shares to trade under the ticker &#8220;CNCK,&#8221; according to a press release.
"We are incredibly proud and excited to become a Nasdaq-listed company and for what the future holds for the Coincheck group companies and our shareholders," said Oki Matsumoto, Coincheck's Executive Chairman.
To mark the occasion, Matsumoto rang the opening bell. Shares of Coincheck were up 0.22% in after-hours trading to $13.38.&nbsp;
See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42382883/ark-invests-cathie-wood-hails-bitcoins-100k-climb-as-a-big-deal-labels-apex-crypto-as-gold-substitute-and-emerging-reserve-currency">Ark Invest&#8217;s Cathie Wood Hails Bitcoin&#8217;s $100K Climb As A &#8216;Big Deal,&#8217; Labels Apex Crypto As Gold Substitute And Emerging Reserve Currency</a>
Why It Matters: Coincheck is one of Japan's biggest cryptocurrency exchanges, recognized as the country's most-downloaded trading app for five consecutive years. It supported trading in cryptocurrencies like Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>), Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>), and Litecoin (CRYPTO: LTE) among others.
With the debut, Coincheck became only the second publicly-listed company on Nasdaq with cryptocurrency trading as its core business, after Coinbase.
Photo Courtesy: Piotr Swat on Shutterstock.com
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42405504/dogecoin-can-touch-18-if-things-go-wild-says-influential-crypto-trader-thankful-for-the-dip-and-will-buy-more">Dogecoin Can Touch $18 If Things &#8216;Go Wild,&#8217; Says Influential Crypto Trader: &#8216;Thankful For The Dip And Will Buy More&#8217;</a></li>
<li></li>
</ul>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

General

$BTC

$ETH

CNCK

Japan's Coincheck Crypto Exchange Enters Wall Street With Nasdaq Listing

Microsoft Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) is reportedly making significant strides in AI healthcare by recruiting former Alphbaet Inc.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) Google DeepMind staff.
What Happened Mustafa Suleyman, who <a href="https://www.benzinga.com/news/24/05/38664730/googles-deepmind-co-founder-mustafa-suleyman-shares-his-exciting-first-month-at-microsoft-truly-tran">co-founded DeepMind</a> in 2010 and is now Microsoft&#8217;s AI head, is spearheading this initiative, <a href="https://www.ft.com/content/c41b9dec-d823-466f-a880-d223e3c34e19">reported</a> the Financial Times.
He has brought on board Dominic King, the ex-head of DeepMind's health unit, as vice-president of Microsoft&#8217;s new AI health team in London.
Christopher Kelly, a clinical research scientist from DeepMind, has also joined the team, along with two other former colleagues from the AI start-up.
See Also: <a href="https://www.benzinga.com/media/24/12/42407739/trump-announces-plans-to-have-dinner-with-amazon-founder-jeff-bezos-as-billionaire-rivals-turn-unexpected-allies-after-years-of-clashes?itm_source=parsely-api">Trump Announces Plans To Have Dinner With Amazon Founder Jeff Bezos As Billionaire Rivals Turn Unexpected Allies After Years Of Clashes</a>
Microsoft&#8217;s new consumer AI health division aims to leverage generative AI for health-related applications, addressing the growing trend of consumers seeking health information online.
Microsoft confirmed the establishment of its new unit in a statement to the report, underscoring the importance of health as a critical use case for responsible AI. &#8220;We continue to hire top talent in support of these efforts.&#8221;
Microsoft did not immediately respond to <a href="https://pro.benzinga.com/dashboard">Benzinga's</a> request for comments.
Subscribe to the <a href="https://bztechtrends.beehiiv.com/subscribe">Benzinga Tech Trends newsletter</a> to get all the latest tech developments delivered to your inbox.
Why It Matters: The healthcare sector has emerged as a significant growth area in the ongoing AI boom.&nbsp;
According to a 2023 <a href="https://www2.deloitte.com/in/en/pages/life-sciences-and-healthcare/articles/consumers-believe-generative-AI-could-make-health-care-more-affordable.html">survey </a>by Deloitte&#8217;s Center for Health Solutions, involving 2,014 U.S. adults, over half (53%) of respondents believe generative AI could improve access to healthcare, while 46% think it holds promise for reducing healthcare costs.
Moreover, 48% of the people said they use generative AI chatbots like OpenAI's ChatGPT, Google Gemini, Microsoft Copilot, and Claude to ask for health-related help.
Meanwhile, Microsoft has been <a href="https://www.benzinga.com/24/11/42088290/microsoft-defies-the-ai-plateau-pushing-boundaries-with-new-scaling-laws">actively pushing the boundaries</a> of AI. At its Ignite conference last month, the company unveiled over 80 product enhancements.
At the time, JPMorgan analyst Mark Murphy said that Microsoft is uniquely positioned in the market, infusing GenAI across both application and infrastructure stacks.
<a href="https://www.benzinga.com/markets/equities/24/10/41643178/microsofts-ai-business-set-to-hit-10b-revenue-milestone-in-q2-satya-nadella-says-it-is-the-faste">Microsoft&#8217;s AI business</a> is also on track to surpass a $10 billion annual revenue run rate, marking it as the fastest-growing segment in the company&#8217;s history. CEO Satya Nadella highlighted the rapid adoption of AI across the company&#8217;s product portfolio during its <a href="https://www.benzinga.com/news/earnings/24/10/41636770/microsoft-q1-earnings-highlights-ai-driven-transformation-is-changing-work-company-beats-revenue-ep">first quarter earnings</a> call.
Check out more of Benzinga&#8217;s Consumer Tech coverage by&nbsp;<a href="https://www.benzinga.com/topic/consumer-tech" target="_blank" rel="noreferrer noopener">following this link</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/tech/24/12/42312508/tesla-ceo-elon-musk-agrees-with-apple-co-founder-steve-jobs-on-guiding-talent-you-know-who-the-best-managers-are?itm_source=parsely-api">Tesla CEO Elon Musk Agrees With Apple Co-Founder Steve Jobs On Guiding Talent: &#8216;You Know Who The Best Managers Are?&#8217;</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.

Comments

Medmix

Medmix (MDMXF) Forecast

Medmix (OTC:MDMXF) Stock, Quote.Headers.trade-ideas

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga